SCHEMBL9166348

SCHEMBL9166348

CCc1cc(NCc2nc3c(Cl)cccc3o2)c(=O)[nH]c1C

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 2/20 0.37
PARP1 P09874 1/20 0.35
CD38 P28907 9/20 0.35
CYP3A4 P08684 3/20 0.34
PTGES O14684 1/20 0.34
NR4A2 P43354 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CB P42338 1/20 0.33
PIK3CG P48736 1/20 0.33
FABP4 P15090 1/20 0.33
F2 P00734 1/20 0.33
FBP1 P09467 1/20 0.32
CDK5 Q00535 1/20 0.32
CDK5R1 Q15078 1/20 0.32
ALDH1A1 P00352 1/20 0.32
GLA P06280 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9166681 0.88 PIK3CD (0.41) IDH1PARP1CD38CYP3A4PIK3CD
L-697661 SCHEMBL599639 0.85 FABP4 (0.34) IDH1FABP4ALDH1A1GLA
L-697661 SCHEMBL29456987 0.85 FABP4 (0.34) IDH1FABP4ALDH1A1GLA
SCHEMBL9168366 0.83 MTNR1A (0.37) PARP1
SCHEMBL9281450 0.83 RAB9A (0.41) PIK3CDPIK3CB
SCHEMBL9846224 0.82 PARP1 (0.37) PARP1PTGESPIK3CDPIK3CBPIK3CG
SCHEMBL9846291 0.81 PARP1 (0.35) IDH1PARP1CD38CYP3A4PTGES
SCHEMBL9171193 0.80 FABP4 (0.34) IDH1CD38CYP3A4FABP4
SCHEMBL29456981 0.78 KMT2A (0.35) ALDH1A1GLA
SCHEMBL6367001 0.78 KMT2A (0.35) ALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0650362-A1 ANTIVIRAL COMBINATIONS GLAXO GROUP LIMITED (GB) 1995-05-03 EP claimed
WO-1994002154-A1 ANTIVIRAL COMBINATIONS GLAXO GROUP LIMITED (GB) 1994-02-03 WO claimed
EP-0577243-A2 Recombinant human HIV-neutralizing monoclonal antibodies for prevention and treatment of HIV infection MERCK & CO. INC. (US) 1994-01-05 EP claimed
WO-1993019785-A1 RECOMBINANT HUMAN HIV-NEUTRALIZING MONOCLONAL ANTIBODIES FOR PREVENTION AND TREATMENT OF HIV INFECTION MERCK & CO., INC. (US) 1993-10-14 WO claimed
EP-0484071-A2 Synergism of HIV reverse transcriptase inhibitors MERCK & CO. INC. (US) 1992-05-06 EP claimed
EP-0462800-A2 Inhibitors of HIV reverse transcriptase MERCK & CO. INC. (US) 1991-12-27 EP claimed
EP-0666744-A1 USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION THE UPJOHN COMPANY (US) 1995-08-16 EP disclosed
EP-0650362-A1 ANTIVIRAL COMBINATIONS GLAXO GROUP LIMITED (GB) 1995-05-03 EP disclosed
WO-1994009781-A1 USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION THE UPJOHN COMPANY (US) 1994-05-11 WO disclosed
WO-1994002154-A1 ANTIVIRAL COMBINATIONS GLAXO GROUP LIMITED (GB) 1994-02-03 WO disclosed
EP-0577243-A2 Recombinant human HIV-neutralizing monoclonal antibodies for prevention and treatment of HIV infection MERCK & CO. INC. (US) 1994-01-05 EP disclosed
WO-1993019785-A1 RECOMBINANT HUMAN HIV-NEUTRALIZING MONOCLONAL ANTIBODIES FOR PREVENTION AND TREATMENT OF HIV INFECTION MERCK & CO., INC. (US) 1993-10-14 WO disclosed
EP-0484071-A2 Synergism of HIV reverse transcriptase inhibitors MERCK & CO. INC. (US) 1992-05-06 EP disclosed